Viltepso (viltolarsen) (for Ohio Only)
This Ohio-only UnitedHealthcare Medical Benefit Drug Policy defines coverage criteria, prior authorization and documentation requirements for Viltepso (viltolarsen) to treat Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.
Coverage criteria revised to add a requirement that Viltepso will not be used concomitantly with Duvyzat (givinostat).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.